Skip to content
Dosage GuideResearch Reference

BPC-157 Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for BPC-157. All information is for educational purposes only.

Quick Answer

In preclinical research, BPC-157 is typically administered at 200–500 mcg per dose, 1–2 times daily via subcutaneous or intramuscular injection near the injury site. For gut-related conditions, oral capsule doses of 500–1,000 mcg are used given its unusual stability in gastric acid. No human clinical dose-ranging trials have been completed.

→ BPC-157 Benefits→ BPC-157 Side Effects→ Full BPC-157 Profile
Table of Contents

Standard Dosage Range

Research dosing range: 200–500 mcg per dose (injection); 500–1,000 mcg (oral)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Musculoskeletal Injury (tendons, ligaments)

200–500 mcg1–2× daily
Duration

4–8 weeks

Inject subcutaneously near the injury site. Many researchers prefer bilateral injection closest to the area being targeted. Most preclinical studies used a 4-week protocol.

Gastrointestinal Healing (leaky gut, IBS, ulcers)

500–1,000 mcg1–2× daily
Duration

4–6 weeks

Oral administration (capsule or dissolved in water) is preferred for GI conditions. BPC-157 is uniquely stable in gastric acid, making it one of the few peptides viable orally.

Muscle Tear / Strain

250–500 mcg2× daily
Duration

3–6 weeks

Subcutaneous injection. Some protocols pair BPC-157 with TB-500 for synergistic muscle and connective tissue repair.

Neuroprotection / Traumatic Brain Injury

200–400 mcg1× daily
Duration

4–12 weeks

Evidence is preliminary (rat models only). Intraperitoneal administration used in studies; subcutaneous is the practical analog for research purposes.

Systemic Anti-Inflammatory

250 mcg1× daily
Duration

4–8 weeks

Lower dose for systemic use. Subcutaneous or oral. Not yet validated in human trials.

Timing & Frequency

For musculoskeletal applications, injections are typically administered in the morning or post-workout, near the injury site. For GI conditions, oral dosing 30 minutes before meals may improve delivery. BPC-157 has an estimated half-life of ~4 hours, supporting twice-daily dosing for sustained coverage in preclinical models.

Cycle Guidance

Most preclinical studies ran 4–6 week protocols. Common research practice uses a 6–8 week cycle followed by a 4-week break. BPC-157 does not appear to suppress endogenous systems (unlike GH peptides), so cycling rationale is primarily precautionary given limited long-term human safety data.

Reconstitution Reference

Quick reference for reconstituting BPC-157. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 5 mg per vial
BAC Water Volume2.5 mL bacteriostatic water for 2 mg/mL concentration
Concentration & DrawAt 2 mg/mL: 100 mcg = 0.05 mL (5 units on a 100-unit insulin syringe)
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at room temperature or refrigerated.
StabilityReconstituted solution stable up to 30 days refrigerated. Lyophilized powder stable 12–24 months per manufacturer specifications.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the standard BPC-157 dosage for tendon injury?
Preclinical research typically uses 200–500 mcg per dose, administered 1–2 times daily via subcutaneous injection near the injured tendon. The most commonly cited protocol in rat tendon studies is around 10 mcg/kg/day. For a 80 kg human, this approximates 800 mcg/day — though no human dose-ranging studies exist. Most research community protocols use 200–500 mcg twice daily for 4–6 weeks.
Can I take BPC-157 orally instead of injecting?
Yes — BPC-157 is exceptionally stable in gastric acid, unlike most peptides. Oral administration is preferred for gastrointestinal conditions (leaky gut, IBS, ulcers). For musculoskeletal injuries, subcutaneous injection delivers higher local concentrations at the injury site and is generally preferred. Oral doses are typically 2–3× higher than injection doses to account for lower bioavailability.
How do I calculate my BPC-157 injection volume?
Use our Reconstitution Calculator (/tools/reconstitution-calculator) for exact math. Quick reference: If you reconstitute 5 mg of BPC-157 in 2.5 mL of bacteriostatic water, you get a concentration of 2 mg/mL (2,000 mcg/mL). For a 250 mcg dose: 250 ÷ 2,000 = 0.125 mL, which is 12.5 units on a 100-unit insulin syringe.
How long does BPC-157 take to work?
Anecdotal reports commonly note subjective improvements within 1–2 weeks. Preclinical studies measuring objective healing markers (tendon tensile strength, collagen organization) showed significant differences by week 2–4. Gastrointestinal effects may be noticed sooner (within days) for acute gut issues. A full 6–8 week cycle is recommended before assessing results.
Should BPC-157 be injected near the injury site?
For localized musculoskeletal injuries, injecting subcutaneously near (not into) the injury site is preferred by most researchers. This is thought to maximize local peptide concentration. However, preclinical studies have also demonstrated systemic healing effects even with remote injection sites, suggesting systemic distribution contributes to its mechanism.
What is the best BPC-157 cycle length?
Most preclinical studies used 4–6 week protocols. The research community commonly uses 6–8 week cycles. There are no long-term human safety studies, so extended continuous use is not well-characterized. A common approach is 8 weeks on, 4 weeks off, though this cycling rationale is precautionary rather than evidence-based.

References

  1. 1
    Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts(2010)PubMed ↗
  2. 2
    Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract(2011)PubMed ↗
  3. 3
    BPC 157 and its effects on the musculoskeletal system — a systematic review(2020)PubMed ↗
  4. 4
    Pentadecapeptide BPC 157 and its effects in the central nervous system(2020)PubMed ↗
  5. 5
    Stable gastric pentadecapeptide BPC 157 counteracts Cuprizone-induced multiple sclerosis in mice(2016)PubMed ↗
  6. 6
    BPC 157 promotes functional recovery after Achilles tendon to bone reattachment in rats(2018)PubMed ↗

Last updated: 2026-02-26